KHKhê Hoang-Xuan

Khê Hoang-Xuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Khê Hoang-Xuan has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline Houillier

    Neuro-Oncology Department, Institut de Neurologie, Hôpitaux Universitaires Pitié-Salpêtrière–Charles Foix, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne Université, Inserm, CNRS, UMR S1127, Institut du Cerveau (ICM), IHU, Paris, France

    3 shared publications
  • Caroline Houillier

    Service de Neurooncologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, INSERM, CNRS, UMR S 1127, ICM, IHU, Paris, France

    3 shared publications
  • Agusti Alentorn

    Brain Tumor Heterogeneity, Immunity and Therapy (BRIGHT), Paris Brain Institute (ICM), Sorbonne Université, INSERM U1127, CNRS UMR7225, Paris, France

    2 shared publications
  • A. Alentorn

    Service de neurologie 2, CHU Pitié-Salpêtrière, AP-HP, Sorbonne université, 47, boulevard de l'hôpital, 75013 Paris, France; Brain Institute-ICM, Inserm, Sorbonne université, CNRS, Paris, France; LOC network, France

    1 shared publication
  • A. Morales-Martinez

    Service de neurologie 2, CHU Pitié-Salpêtrière, AP-HP, Sorbonne université, 47, boulevard de l'hôpital, 75013 Paris, France

    1 shared publication
  • A. Rachdi

    Service de neurologie 2, CHU Pitié-Salpêtrière, AP-HP, Sorbonne université, 47, boulevard de l'hôpital, 75013 Paris, France; Institut Mongi Ben Hamida de neurologie de Tunis, Tunis, Tunisia

    1 shared publication

Latest Publications

  • Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma

    by Angel Escamilla-Ramírez, Caroline Houillier, Khê Hoang-Xuan

    Purpose of review: Improved survival in primary CNS lymphoma (PCNSL) has increased the importance of delayed treatment-related neurotoxicity as a determinant of functional outcome and quality of life. This review summarizes contemporary evidence on neurocognitive outcomes across modern therapies and discusses the challenge of distinguishing neurotoxicity from relapse. Recent findings: Neurotoxicity differs by treatment modality. Consolidation whole-brain radiotherapy (WBRT) after high-dose methotrexate-based induction remains most strongly associated with delayed cognitive decline, white matter injury, and cerebral atrophy. High-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) in fit patients and low-dose WBRT are effective consolidation strategies with better cognitive preservation. CAR T-cell therapy has introduced distinct inflammatory syndromes usually reversible, including immune effector cell-associated neurotoxicity syndrome (ICANS) characterized by stereotyped cognitive dysfunctions and tumor inflammation-associated neurotoxicity (TIAN), which can mimic focal progression. Bispecific antibodies’ neurotoxicity profile resembles to that of CAR T-cell therapy with a lower rate of ICANS. Multimodal monitoring using neuropsychological testing, advanced neuroimaging, cerebrospinal fluid biomarkers, and circulating tumor DNA may improve diagnostic accuracy. Summary: Future therapeutic progress in PCNSL should prioritize prediction, early detection, and prevention of neurotoxicity alongside disease control.

    • 8 February 2024
    • Published by HAL in HAL
    Open Access

    Comparing foundation models and nnU-Net for segmentation of primary brain lymphoma on clinical routine post-contrast T1-weighted MRI

    by Guanghui Fu, Lucia Nichelli, Dario Herran, Romain Valabregue, Agusti Alentorn, Khê Hoang-Xuan, Caroline Houillier, Didier Dormont, Stéphane Lehéricy, Olivier Colliot

    Primary Central Nervous System (PCNS) lymphoma is an aggressive brain tumor with variable response rates to current therapeutic strategies. Segmentation of PCNS lymphoma on magnetic resonance imaging (MRI) is important to enhance diagnosis and follow-up. However, it is a difficult task due to the highly variable presentation of lymphoma lesions and the heterogeneity of acquisitions in clinical routine. The recent rise of foundation models (FM) for segmentation, such as Segment Anything Model (SAM), offers a potential alternative to classical supervised deep learning approaches. Nevertheless, their value on challenging tasks such as lymphoma segmentation on clinical routine data has not been thoroughly studied. In this paper, we assessed the performance of several FMs (SAM, MedSAM, UniverSeg) for lymphoma segmentation and compared them to a classical supervised learning with nnU-net. In addition, we performed experiments on the public dataset MSD-BraTS so that others can reproduce our findings. We found that nnU-net outperformed FMs by vast and statistically significant margins. For the lymphoma clinical routine dataset, the difference between nnU-Net and the best FM was about 19 percent points of Dice. For MSD-BraTS, it was about 10 percent points. Our findings suggest that current FMs fall short in handling complex segmentation tasks in particular on clinical routine data and that 3D supervised learning (e.g. with nnU-Net) is essential at present. Trained models for both tasks, code and box prompts (for MSD-BraTS) are available at: https://github.com/GuanghuiFU/medical_cv_foundation_eval.

  • Recent advances in the diagnosis and the treatment of primary CNS lymphoma

    by A. Rachdi, H. Hernandez-Tost, D. Herzi, A. Morales-Martinez, I. Hernández-Verdin, C. Houillier, A. Alentorn, K. Hoang-Xuan


  • Open Access

    Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later

    by Monica Ribeiro, Mohamed Amine Benadjaoud, Laura Moisy, Julian Jacob, Loïc Feuvret, Alexander Balcerac, Marie-Odile Bernier, Dimitri Psimaras, Khê Hoang-Xuan, Georges Noel, et al.

    High-grade glioma (HGG) is associated with several external and internal stressors that may induce mood alterations at all stages of the disease. Symptoms of depression and anxiety in persons with glioma have multifactorial etiology and require active follow-up. We reviewed the literature data on the prevalence, mechanisms likely involved in the etiology of mood alterations in persons with HGG and psychosocial interventions found beneficial in treating these symptoms. We also investigated the prevalence and clinical variables that could increase the risk of depression and anxiety symptoms in a group of patients with HGG at two disease time-points: after surgery, before and 1 year after chemoradiotherapy. Literature findings revealed complex mechanisms underlying these symptoms and highlighted the importance of providing early access to palliative care. Our results show a high rate of anxiety and depression symptoms in the first stage of the disease and increased concomitance of these symptoms at the 1-year follow-up. Depression and anxiety symptoms at 1 year after the end of chemoradiotherapy were associated with the presence of symptoms at the first stage of the disease and tumor progression. Antiepileptic drugs and corticosteroid intake did not increase the risk of depressive and anxious symptoms among patients. Active management of mood alterations is an essential part of the care and contributes to patients’ well-being and quality of life.


  • Prognostic factors in primary central nervous system lymphoma

    by Andrea Morales-Martinez, Lucia Nichelli, Isaias Hernandez-Verdin, Caroline Houillier, Agustí Alentorn, Khê Hoang-Xuan

    Purpose of review: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal diffuse large B cell lymphoma. Despite its apparent immunopathological homogeneity, PCNSL displays a wide variability in outcome. Identifying prognostic factors is of importance for patient stratification and clinical decision-making. The purpose of this review is to focus on the clinical, neuroradiological and biological variables correlated with the prognosis at the time of diagnosis in immunocompetent patients. Recent findings: Age and performance status remain the most consistent clinical prognostic factors. The current literature suggests that neurocognitive dysfunction is an independent predictor of poor outcome. Cumulating data support the prognostic value of increased interleukin-10 level in the cerebrospinal fluid (CSF), in addition to its interest as a diagnostic biomarker. Advances in neuroimaging and in omics have identified several semi-quantitative radiological features (apparent diffusion restriction measures, dynamic contrast-enhanced perfusion MRI (pMRI) pattern and 18F-fluorodeoxyglucose metabolism) and molecular genetic alterations with prognostic impact in PCNSL. Summary: Validation of new biologic and neuroimaging markers in prospective studies is required before integrating future prognostic scoring systems. In the era of radiomic, large clinicoradiological and molecular databases are needed to develop multimodal artificial intelligence algorithms for the prediction of accurate outcome.


  • Open Access

    Role of Positron Emission Tomography in Primary Central Nervous System Lymphoma

    by Laura Rozenblum, Caroline Houillier, Carole Soussain, Marc Bertaux, Sylvain Choquet, Damien Galanaud, Khê Hoang-Xuan, Aurélie Kas

    The incidence of primary central nervous system lymphoma has increased over the past two decades in immunocompetent patients and the prognosis remains poor. A diagnosis and complete evaluation of the patient is needed without delay, but histologic evaluation is not always available and PCNSL can mimic a variety of brain lesions on MRI. In this article, we review the potential role of 18F-FDG PET for the diagnosis of PCNSL in immunocompetent and immunocompromised patients. Its contribution to systemic assessment at the time of diagnosis has been well established by expert societies over the past decade. In addition, 18F-FDG provides valuable information for differential diagnosis and outcome prediction. The literature also shows the potential role of 18F-FDG as a therapeutic evaluation tool during the treatment and the end of the treatment. Finally, we present several new radiotracers that may have a potential role in the management of PCNSL in the future.


  • Top Cited Papers
    Open Access

    European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

    by Khê Hoang-Xuan, Martina Deckert, Andrés J M Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, et al.

    The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.


  • Open Access

    Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives

    by Andrea Morales-Martinez, Fernando Lozano-Sanchez, Alberto Duran-Peña, Khe Hoang-Xuan, Caroline Houillier

    The management of elderly patients suffering from primary central nervous system (CNS) lymphoma, who represent a rapidly growing population, is challenging. Despite the advances made in PCNSL treatment, the prognosis in older patients remains unsatisfactory. The high risk of systemic and CNS toxicity induced by a high-dose chemotherapy regimen and radiation therapy, respectively, limits the use of consolidation phase treatments in elderly patients and contributes to the poor outcome of these patients. Here, we review the current treatment strategies and ongoing trials proposed for elderly PCNSL patients.


  • Open Access

    Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome

    by Guillaume Taieb, Elsa Kaphan, Claire Duflos, Christine Lebrun-Frénay, Valérie Rigau, Eric Thouvenot, Emeline Duhin-Gand, Romain Lefaucheur, Khe Hoang-Xuan, Sarah Coulette, et al.

    Objective To determine whether adult cases of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS) may be related to familial hemophagocytic lymphohistiocytosis (HLH) causes, we have screened patients with adult-onset CLIPPERS for mutations in primary HLH-associated genes. Methods In our cohort of 36 patients fulfilling the criteria for probable or definite CLIPPERS according to the CLIPPERS-2017 criteria, we conducted a first study on 12 patients who consented to genetic testing. In these 12 patients, systemic HLH criteria were searched, and genetic analysis of 8 genes involved in primary HLH was performed. Results Four definite and 8 probable CLIPPERS were enrolled (n = 12). Mutations involved in HLH were identified in 2 definite and 2 probable CLIPPERS (4/12). Three of them had biallelic PRF1 mutations with reduced perforin expression in natural killer cells. The remaining patient had biallelic UNC13D mutations with cytotoxic lymphocyte impaired degranulation. None of the mutated patients reached the criteria for systemic HLH. During follow-up, 3 of them displayed atypical findings for CLIPPERS, including emergence of systemic non-Hodgkin lymphoma (1/3) and confluent gadolinium-enhancing lesions on brain MRI (3/3). Conclusions In our patients presenting with adult-onset CLIPPERS, one-third have HLH gene mutations. This genetic treatable condition should be searched in patients with CLIPPERS, especially in those presenting with atypical findings.


  • Open Access

    Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin’s Lymphomas from Genome-Wide Association Studies

    by Isaias Hernández-Verdin, Karim Labreche, Marion Benazra, Karima Mokhtari, Khê Hoang-Xuan, Agusti Alentorn

    B-cell non-Hodgkin’s lymphoma (NHL) risk associations had been mainly attributed to family history of the disease, inflammation, and immune components including human leukocyte antigen (HLA) genetic variations. Nevertheless, a broad range of genome-wide association studies (GWAS) have shed light into the identification of several genetic variants presumptively associated with B-cell NHL etiologies, survival or shared genetic risk with other diseases. The present review aims to overview HLA structure and diversity and summarize the evidence of genetic variations, by GWAS, on five NHL subtypes (diffuse large B-cell lymphoma DLBCL, follicular lymphoma FL, chronic lymphocytic leukemia CLL, marginal zone lymphoma MZL, and primary central nervous system lymphoma PCNSL). Evidence indicates that the HLA zygosity status in B-cell NHL might promote immune escape and that genome-wide significance variants can give biological insight but also potential therapeutic markers such as WEE1 in DLBCL. However, additional studies are needed, especially for non-DLBCL, to replicate the associations found to date.